TY - JOUR
T1 - Comparison of interleukin-1β expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma
AU - Lacy, Martha Q.
AU - Donovan, Kathleen A.
AU - Heimbach, Julie K.
AU - Ahmann, Gregory J.
AU - Lust, John A.
PY - 1999/1/1
Y1 - 1999/1/1
N2 - We investigated whether interleukin-1β (IL-1β) is differentially expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients because IL-1β appears to play a major role in the development of lyric bone lesions, the major clinical feature distinguishing MGUS from myeloma. In situ hybridization (ISH) for IL-1β was performed using bone marrow aspirates from 51 MM, 7 smoldering MM, 21 MGUS, and 5 normal control samples. Using the ISH technique IL-1β mRNA was detectable in the plasma cells from 49 of 51 patients with active myeloma and 7 of 7 patients with smoldering myeloma. In contrast, 5 of 21 patients with MGUS and 0 of 5 normal controls had detectable IL-1β message. Bone lesions were present in 40 of the 51 MM patients analyzed, and all 40 patients had IL-1β mRNA by ISH. These results show that greater than 95% of MM patients but less than 25% of MGUS patients are positive for IL- 1β production. In the future, continued follow-up of IL-1β positive and negative MGUS patients should determine whether aberrant expression of plasma cell IL-1β is predictive of those MGUS patients that will eventually progress to active myeloma.
AB - We investigated whether interleukin-1β (IL-1β) is differentially expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients because IL-1β appears to play a major role in the development of lyric bone lesions, the major clinical feature distinguishing MGUS from myeloma. In situ hybridization (ISH) for IL-1β was performed using bone marrow aspirates from 51 MM, 7 smoldering MM, 21 MGUS, and 5 normal control samples. Using the ISH technique IL-1β mRNA was detectable in the plasma cells from 49 of 51 patients with active myeloma and 7 of 7 patients with smoldering myeloma. In contrast, 5 of 21 patients with MGUS and 0 of 5 normal controls had detectable IL-1β message. Bone lesions were present in 40 of the 51 MM patients analyzed, and all 40 patients had IL-1β mRNA by ISH. These results show that greater than 95% of MM patients but less than 25% of MGUS patients are positive for IL- 1β production. In the future, continued follow-up of IL-1β positive and negative MGUS patients should determine whether aberrant expression of plasma cell IL-1β is predictive of those MGUS patients that will eventually progress to active myeloma.
UR - http://www.scopus.com/inward/record.url?scp=0032954020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032954020&partnerID=8YFLogxK
U2 - 10.1182/blood.v93.1.300.401k36_300_305
DO - 10.1182/blood.v93.1.300.401k36_300_305
M3 - Article
C2 - 9864174
AN - SCOPUS:0032954020
SN - 0006-4971
VL - 93
SP - 300
EP - 305
JO - Blood
JF - Blood
IS - 1
ER -